Building from the success of our programs in endocrinology, our vision in oncology is to create best-in-class therapeutics by applying both systemic and sustained localized TransCon technologies for clinically validated pathways. By applying our unique algorithm for product innovation, we believe we can improve outcomes in oncology currently limited by suboptimal efficacy and systemic toxicity.
TransCon is particularly well-suited to oncology because of the large number of validated targets with known limitations. We are working to not only prolong the activity of drugs at the efficacious levels, but to extend the exposure times without reaching high levels of toxicity that often complicate oncology therapeutic regimens. By prolonging therapeutic levels, we have the potential to enable superior efficacy of small molecules, peptides and proteins without increased toxicity – addressing a long-standing challenge in oncology.
Currently, we have three oncology programs in preclinical studies: TransCon TLR7/8 Agonist, TransCon IL-2 β/γ and TransCon Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (VEGF-TKI). TransCon IL-2 β/γ is intended for systemic administration, while TransCon TLR7/8 Agonist and TransCon VEGF-TKI were designed to address the limitations of intratumoral treatments. These programs have potential to target multiple steps of the immunity cycle that drives the immune response against tumor cells. Our goal is to file an IND or equivalent in this area by the end of 2020.
TransCon Immunity Cycle Seeks Broad Impact
TransCon technologies for sustained localized and systemic delivery have the potential to broadly impact the immunity cycle and potentially improve outcomes by focusing on validated mechanisms.